{
    "nctId": "NCT02305628",
    "briefTitle": "An Observational Study of Herceptin SC Safety in Breast Cancer",
    "officialTitle": "Post-Marketing Surveillance of Herceptin Subcutaneous in Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 600,
    "primaryOutcomeMeasure": "Safety (composite outcome measure): Incidence of adverse events (AEs), serious adverse events (SAEs), adverse events of special interest, pregnancies, adverse drug reactions (ADRs); unexpected ADRs; expected ADRs",
    "eligibilityCriteria": "Inclusion Criteria:\n\n- All patients administered Herceptin SC for the locally approved indications\n\nExclusion Criteria:\n\nN/A",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}